ClinicalTrials.gg
CompletedNCT04572685Updated Nov 9, 2020

Evaluate the PK of LY03010 Process 1 and Process 2 Drug Product vs INVEGA SUSTENNA After Intramuscular Injection in Schizophrenia Patients

A Phase 1 interventional study of Paliperidone Palmitate in Schizophrenia Patients, sponsored by Luye Pharma Group Ltd.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-11-09.

Sponsored by Luye Pharma Group Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2020, 6 years 4 months ago, and no results have been posted to the registry.
  • Registered 3 months after the study started (first participant enrolled Jan 2020, registered May 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 115 studies testing paliperidone in Schizophrenia — 6 open to participants now, 6 under way, none of them phase 3. paliperidone · Schizophrenia.

Enrollment
98th of 115
36 · median 178
Started
2020
the only one that year
Phase 1
21 of 115
none open now
Registered
105th of 115
by date
Lead sponsor
3 of 115
Luye Pharma Group Ltd.

Among the 115 studies testing paliperidone in Schizophrenia, this one is the 98th largest by enrollment, is the only one that started in 2020, is one of 21 in phase 1, and was the 105th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

6 of the 115 studies testing paliperidone in Schizophrenia are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About paliperidone

paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies testing paliperidone in Schizophrenia, or all of them as a file.
02

Study summary

The primary objectives of the study are to characterize the pharmacokinetic (PK) profiles of paliperidone in LY03010 P1 and P2 following a single IM injection in schizophrenia patients and to compare the PK of LY03010 P1 and P2 with that of INVEGA SUSTENNA® following a single IM injection of 156 mg dosage level.

Read the detailed description

This is a randomized, open-label, parallel-group, single-dose study. Patients will undergo screening evaluations to determine eligibility within 28 days prior to study drug administration. About 36 patients will be randomized in a 1:1:1 ratio to 1 of 3 treatment groups. Patients will be admitted to the clinical facility the day before dosing (Day 0) and will be receiving an IM injection of study drug and completing the assigned study activity including PK sample collection on Day 1. Patients will be discharged on Day 2 after PK collection. All patients will return to the clinical site at designated study days for PK sample collections and assigned clinical procedures. End of study evaluation will be completed on Day 120.

Pharmacokinetics of the study medication will be assessed as primary outcome. Participants' safety will be monitored throughout the study.

03

Conditions studied

  • Schizophrenia Patients

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female ≥18 to ≤65 years of age who meets diagnostic criteria for schizophrenia according to the Fifth Edition (DSM-V) for at least 1 year before screening
  • Have been on a stable dose of oral antipsychotic medication(s) other than risperidone, paliperidone, clozapine, ziprasidone, or thioridazine for at least 4 weeks prior to screening
  • Clinically stable based on clinical assessments and a Positive and Negative Syndrome Scale (PANSS) total score ≤70 as well as a PANSS HATE (hostility, anxiety, tension and excitement) subtotal score \<16 at screening
  • Clinical Global Impression-Severity (CGI-S) score of 1 to 4, inclusive
  • (BMI) ≥17.0 and ≤37kg/m2; body weight ≥50 kg
  • Creatinine level within the normal range
  • All female patients ( and non-childbearing potential) must have a negative pregnancy test result at both screening and baseline.
  • Sexually active fertile male patients must be willing to use acceptable methods (such as double barrier methods of a combination of male condom with either cap, diaphragm or sponge with spermicide) from study drug dosing, throughout the study, and for another 80 days after the EOT visit (or at least 200 days after the dose, whichever is longer) if their partners are women of childbearing potential.

Exclusion criteria

Exclusion Criteria:

  • Primary and active Axis I diagnosis other than schizophrenia
  • Patients who meet DSM-V criteria for substance abuse (moderate or severe) with the exception of caffeine or nicotine in the past 6 months prior to screening, or test positive for barbiturate or alcohol at screening or baseline
  • Patients who received any of following treatment:

    • Use of oral risperidone or paliperidone within 2 weeks before screening.
    • Use of clozapine, thioridazine or ziprasidone within 4 weeks before screening.
    • Use of 2-week depot formulation of risperidone within 3 months, 1-month depot formulation of risperidone or 9-hydroxy risperidone (INVEGA SUSTENNA) within 1 year,
  • Known or suspected or intolerance of risperidone, paliperidone, or any of their (oral risperidone tolerability test should be completed during the screening period
  • interval greater than 450 msec for males and 470 msec for females or a prior history or presence of circumstances
  • Medical history (within 2 years) of , gastrointestinal, cardiovascular, cerebrovascular, musculoskeletal, endocrine, hematologic, renal, hepatic, bronchopulmonary, neurologic, immunologic disorders, or drug hypersensitivity which, in the judgement of the Investigator, would interfere with the patient's ability to participate in the study
  • History of dementia-related psychosis or Parkinson's Disease
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    LY03010 Process 1

    Drug Product of Process 1 ( P1): 156 mg/vial; Single Injection on Day 1 during the entire 120 Day's study. LY03010 P1 using a non-sterile Active Pharmaceutical Ingredients (API) with an absolute ethanol recrystallization was manufactured by an optimized production process

    Drug: Paliperidone Palmitate

  • Experimental
    LY03010 Process 2

    Drug Product of Process 2 (P2): 156 mg/vial; Single Injection on Day 1 during the entire 120 Day's study. LY03010 P2 using a sterile Active Pharmaceutical Ingredients (API) with an isopropanol recrystallization was manufactured by the same optimized production process as that used in P1.

    Drug: Paliperidone Palmitate

  • Experimental
    INVEGA SUSTENNA

    INVEGA SUSTENNA 156 mg/vial; Single Injection on Day 1 during the entire 120 Day's study

    Drug: Paliperidone Palmitate

Interventions

  • A long acting extended release injectable suspension intended for monthly intramuscular administration

    Also known as: Paliperidone Injectable Product

06

What researchers measure

Primary outcomes

  1. To characterize the Maximum Plasma Concentration [Cmax]of LY03010 P1, P2 and INVEGA SUSTENNA following a single IM injection of 156 mg dosage level in schizophrenia patients

    The Cmax of LY03010 P1, P2 and INVEGA SUSTENNA will be measured

    Time frame: 120-Day

  2. To characterize Area under the plasma concentration versus time curve (AUC) of LY03010 P1 and P2 and INVEGA SUSTENNA following a single IM injection of 156 mg dosage level in schizophrenia patients.

    The AUCs of LY03010 P1, P2 and INVEGA SUSTENNA will be evaluated

    Time frame: 120-Day

  3. To compare the Cmax of LY03010 P1 and P2 with the Cmax of INVEGA SUSTENNA

    The relative bioavailability of LY03010 P1 and P2 to Invega Sustenna will be assessed

    Time frame: 120-Day

  4. To compare the AUCs of LY03010 P1 and P2 with the AUCs of INVEGA SUSTENNA

    The relative bioavailability of LY03010 P1 and P2 to Invega Sustenna will be assessed

    Time frame: 120-Day

Secondary outcomes

  1. To evaluate the safety and tolerability of tested drugs. Safety assessments include Incidence of adverse events.

    AE will be monitored throughout of the study course

    Time frame: 120 day

  2. To evaluate the safety of the tested drugs-- Incident of abnormal vital sign

    Vital Sign will be measured on Day1 ,2, 4, 6, 8,10,12,15, 17,19, 22 ,29, 64, 92 and Day 120

    Time frame: 120 Day

  3. To evaluate the safety of the tested drugs-- Incident of abnormal ECG Findings

    12-Lead ECG will be measured on Day 0, 29, 64, 92 and Day 120

    Time frame: 120 Day

  4. To evaluate any abnormal movement symptoms measured by Abnormal Involuntary Movement Scale (AIMS). AIMS measures movement of each part of body muscle with score range of 0-4, 0 means None and 4 means Severe.

    AIMS will be measured on Day 0, 15, 29, 64, 92 and Day 120

    Time frame: 120-Day

  5. To evaluate any abnormal movement symptoms measured by Barnes Akathisia Rating Scale (BARS). BARS is a rating scale for drug-induced akathisia with a range of 0-14; 0 means Normal and 14 means Severe.

    BARS will be measured on Day 0, 15, 29, 64, 92 and Day 120

    Time frame: 120-Day

  6. To evaluate any suicidal attempts measured by Columbia Suicide Severity Rating Scale ( C-SRRS). C-SRRS measures the suicidal intensity of ideation and attempt with score of 1-5; 1 means the least severe and 5 means the most severe.

    C-SSRS will be measured on Day 0, 29, 64, 92 and Day 120

    Time frame: 120-Day

07

Study locations

1 site
  • Hassman Research Institute
    Berlin, New Jersey 08009, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2020 to primary completion in Jun 2020, 5 months.

Of 108 industry-sponsored phase 1 interventional studies under Schizophrenia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 5 months is below that.

Counting every sponsor, half of 133 studies reached it within 12 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2020
First posted
Oct 1, 2020
StartActual
Jan 22, 2020
Primary completionActual
Jun 26, 2020
CompletionActual
Aug 20, 2020
Last update
Nov 9, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04572685
Collaborators
Alliance for Clinical Trials in Oncology, Evolution Research Group
Responsible party
Sponsor
First posted
Oct 1, 2020
Start date
Jan 22, 2020
Primary completion
Jun 26, 2020
Completion
Aug 20, 2020
Last update
Nov 9, 2020

Study contacts

Luye Pharma
study chair · Luye Pharma Group

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paliperidone

Start the discussion